Literature DB >> 22506612

Androgens and doping tests: genetic variation and pit-falls.

Anders Rane1, Lena Ekström.   

Abstract

The large variation in disposition known for most drugs is also true for anabolic androgenic steroids. Genetic factors are probably the single most important cause of this variation. Further, there are reasons to believe that there is a corresponding variation in efficacy of doping agents. Doped individuals employ a large variety of doping strategies in respect of choice of substance, dose, dose interval, duration of treatment and use of other drugs for enforcement of effects or correction of side effects. Metabolic steps up-stream and down-stream of testosterone are genetically variable and contribute substantially to the variation in disposition of testosterone, the most common doping agent in sports and in society. Large inter- and intra-ethnic variation in testosterone glucuronidation and excretion is described as well as the pit-falls in evaluation of testosterone doping test results. The hydrolysis and bioactivation of testosterone enanthate is also genetically variable yielding a 2-3 fold variation in excretion rate and serum concentration, thereby implicating a substantial variation in 'efficacy' of testosterone. Given this situation it is logical to adopt the new findings in the doping control programme. The population based cut-off level for the testosterone : epitestosterone ratio should be replaced by a Bayesian interpretation of consecutive tests in the same individual. When combined with the above genetic information the sensitivity of the test is considerably improved. The combination of the three approaches should reduce the rate of falsely negative or positive results and the number of expensive follow-up tests, stipulated by the World Anti-Doping Agency.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22506612      PMCID: PMC3394124          DOI: 10.1111/j.1365-2125.2012.04294.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  42 in total

1.  Bayesian detection of abnormal hematological values to introduce a no-start rule for heterogeneous populations of athletes.

Authors:  Neil Robinson; Pierre-Edouard Sottas; Patrice Mangin; Martial Saugy
Journal:  Haematologica       Date:  2007-08       Impact factor: 9.941

2.  A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.

Authors:  Dong Gui Hu; Dione Gardner-Stephen; Gianluca Severi; Philip A Gregory; Joanna Treloar; Graham G Giles; Dallas R English; John L Hopper; Wayne D Tilley; Peter I Mackenzie
Journal:  Mol Pharmacol       Date:  2010-07-13       Impact factor: 4.436

3.  A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men.

Authors:  J Jakobsson; E Palonek; M Lorentzon; C Ohlsson; A Rane; L Ekström
Journal:  Pharmacogenomics J       Date:  2006-09-19       Impact factor: 3.550

4.  Testing for anabolic steroids in hair from two bodybuilders.

Authors:  P Kintz; V Cirimele; H Sachs; T Jeanneau; B Ludes
Journal:  Forensic Sci Int       Date:  1999-05-17       Impact factor: 2.395

5.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).

Authors:  B L Coffman; C D King; G R Rios; T R Tephly
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

6.  Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort.

Authors:  Christopher A Haiman; Stephanie E Riley; Matthew L Freedman; Veronica W Setiawan; David V Conti; Loïc Le Marchand
Journal:  J Clin Endocrinol Metab       Date:  2005-01-05       Impact factor: 5.958

7.  Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y).

Authors:  Charlotte Swanson; Mattias Lorentzon; Liesbeth Vandenput; Fernand Labrie; Anders Rane; Jenny Jakobsson; Sarah Chouinard; Alain Bélanger; Claes Ohlsson
Journal:  J Clin Endocrinol Metab       Date:  2007-06-19       Impact factor: 5.958

8.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women.

Authors:  Alison M Dunning; Mitch Dowsett; Catherine S Healey; Louise Tee; Robert N Luben; Elizabeth Folkerd; Karen L Novik; Livia Kelemen; Saeko Ogata; Paul D P Pharoah; Douglas F Easton; N E Day; Bruce A J Ponder
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

9.  Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Authors:  Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

10.  Genetic determinants of serum testosterone concentrations in men.

Authors:  Claes Ohlsson; Henri Wallaschofski; Kathryn L Lunetta; Lisette Stolk; John R B Perry; Annemarie Koster; Ann-Kristin Petersen; Joel Eriksson; Terho Lehtimäki; Ilpo T Huhtaniemi; Geoffrey L Hammond; Marcello Maggio; Andrea D Coviello; Luigi Ferrucci; Margit Heier; Albert Hofman; Kate L Holliday; John-Olov Jansson; Mika Kähönen; David Karasik; Magnus K Karlsson; Douglas P Kiel; Yongmei Liu; Osten Ljunggren; Mattias Lorentzon; Leo-Pekka Lyytikäinen; Thomas Meitinger; Dan Mellström; David Melzer; Iva Miljkovic; Matthias Nauck; Maria Nilsson; Brenda Penninx; Stephen R Pye; Ramachandran S Vasan; Martin Reincke; Fernando Rivadeneira; Abdelouahid Tajar; Alexander Teumer; André G Uitterlinden; Jagadish Ulloor; Jorma Viikari; Uwe Völker; Henry Völzke; H Erich Wichmann; Tsung-Sheng Wu; Wei Vivian Zhuang; Elad Ziv; Frederick C W Wu; Olli Raitakari; Anna Eriksson; Martin Bidlingmaier; Tamara B Harris; Anna Murray; Frank H de Jong; Joanne M Murabito; Shalender Bhasin; Liesbeth Vandenput; Robin Haring
Journal:  PLoS Genet       Date:  2011-10-06       Impact factor: 5.917

View more
  9 in total

1.  Sex, steroids and anabolic androgens in athletics.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 2.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

3.  Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.

Authors:  Haeyoung Zhang; Abdul Basit; Chris Wolford; Kuan-Fu Chen; Andrea Gaedigk; Yvonne S Lin; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2020-02-12       Impact factor: 6.875

4.  Circulating microRNA-122 as Potential Biomarker for Detection of Testosterone Abuse.

Authors:  Olivier Salamin; Laetitia Jaggi; Norbert Baume; Neil Robinson; Martial Saugy; Nicolas Leuenberger
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Geneticizing Ethnicity and Diet: Anti-doping Science and Its Social Impact in the Age of Post-genomics.

Authors:  Jaehwan Hyun
Journal:  Front Genet       Date:  2017-05-09       Impact factor: 4.599

6.  Pregnancy-Induced Perturbation of Urinary Androgenic Steroid Disposition.

Authors:  Yifat Gadot; John-Olof Thörngren; Emma Eklund; Lena Ekström; Anders Rane
Journal:  J Endocr Soc       Date:  2018-05-23

7.  Urinary Steroid Profile in Elite Female Athletes in Relation to Serum Androgens and in Comparison With Untrained Controls.

Authors:  Emma Eklund; Alexander Andersson; Lena Ekström; Angelica Lindén Hirschberg
Journal:  Front Physiol       Date:  2021-08-30       Impact factor: 4.566

Review 8.  Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.

Authors:  Paul Thoueille; Eva Choong; Matthias Cavassini; Thierry Buclin; Laurent A Decosterd
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.790

9.  Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs.

Authors:  Kathy Bailey; Tahmineh Yazdi; Umesh Masharani; Blake Tyrrell; Anthony Butch; Fred Schaufele
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.